Recent developments, like the rise of Donald Trump, suggest that we shouldn’t take our beloved democratic systems for granted.
Real estate will become the S&P 500’s 11th sector next month. Market historian and money manager Laszlo Birinyi isn’t applauding.
Birinyi, in a Monday note, characterized the move as aimed more “to the benefit of the vendor and not the customer.”
The marijuana industry has clearly reached a new level of mass commercialism and I fear we’re in danger of creating a “Marijuana Industrial Complex” that involves venture capitalists, Wall Street traders, pharmaceutical companies, celebrity branding, government regulation and even mainstream media catering to the marijuana industry.
If there was ever an example of how economic incentives can warp the institutions of justice, local jails are it.
At this very moment, nearly 450,000 Americans are sitting in county jails not because they’ve been charged with a crime, but because they simply don’t have enough money to post bail. And according to a new study, America’s money bail system isn’t just unconstitutional—it’s a fundamental engine of injustice in the United States.
Mylan NV (MYL.O) said on Thursday it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary Clinton joined lawmakers in criticizing the drug's high price.
The company, which did not lower the drug's list price, said it would reduce the patient cost of EpiPen through the use of a savings card, which will cover up to $300 of EpiPen 2-Pak.
America is only middle-of-the-road when it comes to innovation for dollar spent.
Drug pricing in America has gained a lot of attention recently, with the price tags of everything from new cancer medicines to EpiPens skyrocketing. Many have wondered: Is it fair to make life-saving drugs so costly?
In the mythical Land of Theory, where everything ‘just works’, we can connect all the objects in our lives. We have the sensors, the wireless networks, and the computing power, but progress is slow if not comically wrong. Why?
Health insurers have an incentive to enrich shareholders and deny coverage to customers
Whom do U.S. health insurers think they’re kidding?
The answer, of course, is: everybody.